7QH8
CRYSTAL STRUCTURE OF LYSYL-TRNA SYNTHETASE FROM Mycobacterium tuberculosis COMPLEXED WITH L-LYSINE
Summary for 7QH8
Entry DOI | 10.2210/pdb7qh8/pdb |
Descriptor | Lysine--tRNA ligase 1, LYSINE, GLYCEROL, ... (4 entities in total) |
Functional Keywords | ligase, mycobacterium tuberculosis, atp binding |
Biological source | Mycobacterium tuberculosis H37Rv |
Total number of polymer chains | 1 |
Total formula weight | 58428.98 |
Authors | Dawson, A.,Robinson, D.A.,Tamjar, J.,Wyatt, P.,Green, S. (deposition date: 2021-12-10, release date: 2022-10-19, Last modification date: 2024-02-07) |
Primary citation | Green, S.R.,Davis, S.H.,Damerow, S.,Engelhart, C.A.,Mathieson, M.,Baragana, B.,Robinson, D.A.,Tamjar, J.,Dawson, A.,Tamaki, F.K.,Buchanan, K.I.,Post, J.,Dowers, K.,Shepherd, S.M.,Jansen, C.,Zuccotto, F.,Gilbert, I.H.,Epemolu, O.,Riley, J.,Stojanovski, L.,Osuna-Cabello, M.,Perez-Herran, E.,Rebollo, M.J.,Guijarro Lopez, L.,Casado Castro, P.,Camino, I.,Kim, H.C.,Bean, J.M.,Nahiyaan, N.,Rhee, K.Y.,Wang, Q.,Tan, V.Y.,Boshoff, H.I.M.,Converse, P.J.,Li, S.Y.,Chang, Y.S.,Fotouhi, N.,Upton, A.M.,Nuermberger, E.L.,Schnappinger, D.,Read, K.D.,Encinas, L.,Bates, R.H.,Wyatt, P.G.,Cleghorn, L.A.T. Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs. Nat Commun, 13:5992-5992, 2022 Cited by PubMed Abstract: Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis within the clinical setting, there is an urgent need for the development of new, safe and effective treatments. Here the development of a drug-like series based on a fused dihydropyrrolidino-pyrimidine scaffold is described. The series has been developed against M. tuberculosis lysyl-tRNA synthetase (LysRS) and cellular studies support this mechanism of action. DDD02049209, the lead compound, is efficacious in mouse models of acute and chronic tuberculosis and has suitable physicochemical, pharmacokinetic properties and an in vitro safety profile that supports further development. Importantly, preliminary analysis using clinical resistant strains shows no pre-existing clinical resistance towards this scaffold. PubMed: 36220877DOI: 10.1038/s41467-022-33736-5 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.92 Å) |
Structure validation
Download full validation report